Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020–2023)

References

• Christofides A, Konstantinidou E, Jani C, et al. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism. 2021;114:154338. doi: 10.1016/j.metabol.2020.154338
   PubMed Web of Science ®Google Scholar
• Hong F, Pan S, Guo Y, et al. Ppars as nuclear receptors for nutrient and energy metabolism. Molecules. 2019;24(14):2545. doi: 10.3390/molecules24142545
   PubMed Web of Science ®Google Scholar
• Wang S, Dougherty EJ, Danner RL. PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacol Res. 2016;111:76–85. doi: 10.1016/j.phrs.2016.02.028
   PubMed Web of Science ®Google Scholar
• Tyagi S, Gupta P, Saini AS, et al. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2(4):236–240. doi: 10.4103/2231-4040.90879
   PubMedGoogle Scholar
• Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications. Eur J Med Chem. 2019;166:502–513.
   PubMed Web of Science ®Google Scholar
• Tan CK, Zhuang Y, Wahli W. Synthetic and natural peroxisome proliferator-activated receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome. Expert Opin Ther Targets. 2017;21(3):333–348. doi: 10.1080/14728222.2017.1280467
   PubMed Web of Science ®Google Scholar
• Giampietro L, Laghezza A, Cerchia C, et al. Novel phenyldiazenyl fibrate analogues as PPAR α/γ/δ pan-agonists for the amelioration of metabolic syndrome. ACS Med Chem Lett. 2019;10(4):545–551. doi: 10.1021/acsmedchemlett.8b00574
   PubMed Web of Science ®Google Scholar
• Jiang Z, Liu X, Yuan Z, et al. Discovery of a novel selective dual peroxisome proliferator-activated receptor α/δ agonist for the treatment of primary biliary cirrhosis. ACS Med Chem Lett. 2019;10(7):1068–1073. doi: 10.1021/acsmedchemlett.9b00189
   PubMed Web of Science ®Google Scholar
• Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007;1771(8):1065–81. doi: 10.1016/j.bbalip.2007.02.003
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70(3):531–544. doi: 10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Raza S, Rajak S, Upadhyay A, et al. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed). 2021;26(2):206–237. doi: 10.2741/4892
   PubMed Web of Science ®Google Scholar
• Kamata S, Honda A, Ishii I. Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease. Biomolecules. 2023;13(8):1264. doi: 10.3390/biom13081264
   PubMed Web of Science ®Google Scholar
• Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol Life Sci. 2018;75(16):2951–2961. doi: 10.1007/s00018-018-2838-4
   PubMed Web of Science ®Google Scholar
• Cheng HS, Tan WR, Low ZS, et al. Exploration and development of PPAR modulators in health and disease: an update of clinical evidence. Int J Mol Sci. 2019;20(20):5055. doi: 10.3390/ijms20205055
   PubMed Web of Science ®Google Scholar
• Kamata S, Honda A, Ishikawa R, et al. Functional and structural insights into the human PPARα/δ/γ targeting preferences of anti-NASH investigational drugs, Lanifibranor, seladelpar, and Elafibranor. Antioxidants (Basel). 2023;12(8):1523. doi: 10.3390/antiox12081523
   PubMedGoogle Scholar
• Goyal NP, Mencin A, Newton KP, et al. An open label, randomized, multicenter study of elafibranor in children with nonalcoholic steatohepatitis. J Pediatr Gastroenterol Nutr. 2023;77(2):160–165. doi: 10.1097/MPG.0000000000003796
   PubMed Web of Science ®Google Scholar
• Schattenberg JM, Pares A, Kowdley KV, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021;74(6):1344–1354. doi: 10.1016/j.jhep.2021.01.013
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Bowlus CL, Levy C, et al. ELATIVE study investigators’ group. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185
   Web of Science ®Google Scholar
• Boubia B, Poupardin O, Barth M, et al. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) α/γ/δ triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate. J Med Chem. 2018;61(6):2246–2265. doi: 10.1021/acs.jmedchem.7b01285
   PubMed Web of Science ®Google Scholar
• Wettstein G, Luccarini JM, Poekes L, et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatol Commun. 2017;1(6):524–537. doi: 10.1002/hep4.1057
   PubMed Web of Science ®Google Scholar
• Deeks ED. Chiglitazar: First Approval. Drugs. 2022;82(1):87–92. doi: 10.1007/s40265-021-01648-1
   PubMed Web of Science ®Google Scholar
• Wetten A, Jones DEJ, Dyson JK. Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC). Expert Opin Investig Drugs. 2022;31(10):1101–1107. doi: 10.1080/13543784.2022.2130750
   PubMed Web of Science ®Google Scholar
• Bowlus CL, Galambos MR, Aspinall RJ, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022;77(2):353–364. doi: 10.1016/j.jhep.2022.02.033
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Shiffman ML, Gulamhusein A, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023;78(2):397–415. doi: 10.1097/HEP.0000000000000395
   PubMed Web of Science ®Google Scholar
• Univ Zhejiang Technology. PPAR-gamma ligand-4,5-diazafluorene-rhodanine conjugate, preparation method and anti-tumor application thereof. CN113461684A. 2021.
   Google Scholar
• Hernandez-Quiles M, Broekema MF, Kalkhoven E. Ppargamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action. Front Endocrinol. 2021;12:624112. doi: 10.3389/fendo.2021.624112
   PubMed Web of Science ®Google Scholar
• Laganà AS, Vitale SG, Nigro A, et al. Pleiotropic actions of peroxisome proliferator-activated receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: current evidence and future perspectives. Int J Mol Sci. 2016;17(7):999. doi: 10.3390/ijms17070999
   PubMed Web of Science ®Google Scholar
• Zaytseva YY, Wallis NK, Southard RC, et al. The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms. Anticancer Res. 2011;31(3):813–23.
   PubMed Web of Science ®Google Scholar
• An Z, Muthusami S, Yu JR, et al. T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. Reprod Sci. 2014;21(11):1352–61. doi: 10.1177/1933719114525265
   PubMed Web of Science ®Google Scholar
• Burton JD, Goldenberg DM, Blumenthal RD. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res. 2008;2008:494161. doi: 10.1155/2008/494161
   PubMed Web of Science ®Google Scholar
• Univ Zhejiang Technology. Aminopyrimidine butenone derivative as PPAR-gamma modulator. CN111018834A. 2020.
   Google Scholar
• Univ Zhejiang Sience & Technology. PPAR gamma targeted glycyrrhetinic acid derivative and preparation method and application thereof. CN114014905A. 2021.
   Google Scholar
• Ming LJ, Yin AC. Therapeutic effects of glycyrrhizic acid. Nat Prod Commun. 2013;8(3):415–418. doi: 10.1177/1934578X1300800335
   PubMed Web of Science ®Google Scholar
• Sun J, Liu HY, Lv CZ, et al. Modification, antitumor activity, and targeted PPARγ study of 18β-glycyrrhetinic acid, an important active ingredient of licorice. J Agric Food Chem. 2019;67(34):9643–9651. doi: 10.1021/acs.jafc.9b03442
   PubMed Web of Science ®Google Scholar
• Yissum Res Dev Co of Hebrew Univ Jerusalem Ltd. Agonists of PPAR-δ. WO2020110126A1. 2020.
   Google Scholar
• Stern N, Goldblum A. Iterative stochastic elimination for solving complex combinatorial problems in drug discovery. ISR J Chem. 2014;54(8–9):1338–1357. doi: 10.1002/ijch.201400072
   Web of Science ®Google Scholar
• Univ China Pharma. Compound with PPAR delta agonistic activity, pharmaceutical composition and medical application. CN112479921A. 2021.
   Google Scholar
• Reneo Pharmaceuticals Inc. Methods of making a PPAR-delta agonist. WO2022115326A1. 2022.
   Google Scholar
• Reneo Pharmaceuticals Inc. Use of PPAR-delta agonists in the treatment of disease. WO2023147309A1. 2023.
   Google Scholar
• Kyungpook Nat Univ Ind Academic Coop Found. Novel PPAR antagonist and pharmaceutical composition for enhancing anti-cancer effect comprising the same. KR102431651B1. 2022.
   Google Scholar
• Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta. 2007;1771(8):991–8. doi: 10.1016/j.bbalip.2007.02.004
   PubMed Web of Science ®Google Scholar
• Sertznig P, Seifert M, Tilgen W, et al. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol. 2008;9(1):15–31. doi: 10.2165/00128071-200809010-00002
   PubMed Web of Science ®Google Scholar
• Medipure Pharmaceuticals Inc. Compounds for treating proliferator-activated receptors (PPAR) mediated diseases or conditions. WO2022221960A1. 2022.
   Google Scholar
• Li Z, Xu Y, Cai Z, et al. Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease. Bioorg Chem. 2020;99:103803. doi: 10.1016/j.bioorg.2020.103803
   PubMed Web of Science ®Google Scholar
• Feng Z, Xiang J, Sun G, et al. Discovery of the first subnanomolar PPARα/δ dual agonist for the treatment of cholestatic liver diseases. J Med Chem. 2023;66(11):7331–7354. doi: 10.1021/acs.jmedchem.2c02123
   PubMed Web of Science ®Google Scholar
• Feng Z, Xiang J, Liu H, et al. Design, synthesis, and biological evaluation of triazolone derivatives as potent PPARα/δ dual agonists for the treatment of nonalcoholic steatohepatitis. J Med Chem. 2022;65(3):2571–2592. doi: 10.1021/acs.jmedchem.1c02002
   PubMed Web of Science ®Google Scholar
• Sichuan Kelun Biotech Biopharmaceutical Co Ltd. Aromatic compound, pharmaceutical composition and use thereof. US11261170B2. 2022.
   Google Scholar
• Li Z, Ren Q, Zhou Z, et al. Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. Eur J Med Chem. 2021;225:113807. doi: 10.1016/j.ejmech.2021.113807
   PubMed Web of Science ®Google Scholar
• Govindarajulu M, Pinky PD, Bloemer J, et al. Signaling mechanisms of selective PPARγ modulators in Alzheimer’s disease. PPAR Res. 2018;2018:2010675. doi: 10.1155/2018/2010675
   PubMed Web of Science ®Google Scholar
• Steinke I, Govindarajulu M, Pinky PD, et al. Selective PPAR-delta/PPAR-gamma activation improves cognition in a model of Alzheimer’s disease. Cells. 2023;12(8):1116. doi: 10.3390/cells12081116
   PubMed Web of Science ®Google Scholar
• Chamberlain S, Gabriel H, Strittmatter W, et al. An exploratory phase IIa study of the PPAR delta/gamma agonist T3D-959 assessing metabolic and cognitive function in subjects with mild to moderate Alzheimer’s disease. J Alzheimers Dis. 2020;73(3):1085–1103. doi: 10.3233/JAD-190864
   PubMed Web of Science ®Google Scholar
• Univ Auburn, Ferris State Univ. Dual PPAR-δ and PPAR-γ agonists for treating disease. US10844003B1. 2020.
   Google Scholar
• Ammazzalorso A, Maccallini C, Amoia P, et al. Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome. Eur J Med Chem. 2019;173:261–273.
   PubMed Web of Science ®Google Scholar
• Schierle S, Neumann S, Heitel P, et al. Design and structural optimization of dual FXR/PPARδ activators. J Med Chem. 2020;63(15):8369–8379. doi: 10.1021/acs.jmedchem.0c00618
   PubMed Web of Science ®Google Scholar
• Blöcher R, Lamers C, Wittmann SK, et al. N-benzylbenzamides: a novel merged scaffold for orally available dual soluble epoxide hydrolase/peroxisome proliferator-activated receptor γ modulators. J Med Chem. 2016;59(1):61–81. doi: 10.1021/acs.jmedchem.5b01239
   PubMed Web of Science ®Google Scholar
• Governa P, Caroleo MC, Carullo G, et al. FFAR1/GPR40: one target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity. Bioorg Med Chem Lett. 2021;41:127969. doi: 10.1016/j.bmcl.2021.127969
   PubMed Web of Science ®Google Scholar
• Rani L, Grewal AS, Sharma N, et al. Recent updates on free fatty acid receptor 1 (GPR-40) agonists for the treatment of type 2 diabetes mellitus. Mini Rev Med Chem. 2021;21(4):426–470. doi: 10.2174/1389557520666201023141326
   PubMed Web of Science ®Google Scholar
• Rady B, Liu J, Huang H, et al. A FFAR1 full agonist restores islet function in models of impaired glucose-stimulated insulin secretion and diabetic non-human primates. Front Endocrinol. 2022;13:1061688. doi: 10.3389/fendo.2022.1061688
   PubMed Web of Science ®Google Scholar
• Tsuda N, Kawaji A, Sato T, et al. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats. Pharmacol Res Perspect. 2017;5(4):e00340. doi: 10.1002/prp2.340
   PubMed Web of Science ®Google Scholar
• Darwish KM, Salama I, Mostafa S, et al. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists. Eur J Med Chem. 2016;109:157–72. doi: 10.1016/j.ejmech.2015.12.049
   PubMed Web of Science ®Google Scholar
• Hidalgo-Figueroa S, Navarrete-Vázquez G, Estrada-Soto S, et al. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: design, synthesis and in combo drug evaluation. Biomed Pharmacother. 2017;90:53–61. doi: 10.1016/j.biopha.2017.03.033
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou Z, Deng F, et al. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ. Eur J Med Chem. 2018;159:267–276. doi: 10.1016/j.ejmech.2018.09.071
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ren Q, Jiao S, et al. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. Eur J Med Chem. 2022;229:114061. doi: 10.1016/j.ejmech.2021.114061
   PubMed Web of Science ®Google Scholar
• Hu L, Zhou Z, Deng L, et al. HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis. J Pharm Pharmacol. 2020;72(11):1564–1573. doi: 10.1111/jphp.13342
   PubMed Web of Science ®Google Scholar
• Li MH, Chen W, Wang LL, et al. RLA8-a new and highly effective quadruple PPAR-α/γ/δ and GPR40 agonist to reverse nonalcoholic steatohepatitis and fibrosis. J Pharmacol Exp Ther. 2019;369(1):67–77. doi: 10.1124/jpet.118.255216.
   PubMed Web of Science ®Google Scholar
• Univ Guangdong Pharm. Novel FFA1 and PPAR alpha/gamma/delta quadruple agonist, preparation method thereof and application of quadruple agonist as medicament. CN112759515A. 2021.
   Google Scholar
• The Second Peoples Hospital of Yunnan Province; Univ Guangdong Pharm. Application of FFA1 and PPAR delta dual agonist. CN113398123A. 2021.
   Google Scholar
• Skerrett R, Pellegrino MP, Casali BT, et al. Combined liver X receptor/Peroxisome proliferator-activated receptor γ agonist treatment reduces amyloid β levels and improves behavior in amyloid precursor Protein/Presenilin 1 mice. J Biol Chem. 2015;290(35):21591–602. doi: 10.1074/jbc.M115.652008
   PubMed Web of Science ®Google Scholar
• Roth JD, Veidal SS, Fensholdt LKD, et al. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Sci Rep. 2019;9(1):9046. doi: 10.1038/s41598-019-45178-z
   PubMedGoogle Scholar
• Leung DTH, Nguyen T, Oliver EM, et al. Combined PPARγ activation and XIAP inhibition as a potential therapeutic strategy for ovarian granulosa cell tumors. Mol Cancer Ther. 2019;18(2):364–375. doi: 10.1158/1535-7163.MCT-18-0078
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi: 10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar
• Yi M, Zheng X, Niu M, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28. doi: 10.1186/s12943-021-01489-2
   PubMed Web of Science ®Google Scholar
• Bahrambeigi S, Molaparast M, Sohrabi F, et al. Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy. Immunol Lett. 2020;220:32–37. doi: 10.1016/j.imlet.2020.01.006
   PubMed Web of Science ®Google Scholar
• Chowdhury PS, Chamoto K, Kumar A, et al. PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8+ T cells and facilitates anti-PD-1 therapy. Cancer Immunol Res. 2018;6(11):1375–1387.
   PubMed Web of Science ®Google Scholar
• Univ Jiangsu. Application of combination of PPAR-alpha (peroxisome proliferator-activated receptor activator-alpha) and PD-1 antibody in preparation of tumor immunotherapy drugs. CN111035765A. 2020.
   Google Scholar
• Univ Jiangsu. Application of PPAR-delta antagonist combined with PD-1 antibody in preparation of tumor immune drug. CN110917347A. 2020.
   Google Scholar
• First Hospital Jilin Univ. Use of PPAR-delta inhibitor in combination with immunotherapeutic drug for preparing anti-tumor drug. WO2022166909A1. 2022.
   Google Scholar
• Univ Jiangsu. Application of PPARG activator and SIRP alpha antibody in preparation of tumor immune drugs. CN112138163A. 2020.
   Google Scholar
• Hayat SMG, Bianconi V, Pirro M, et al. CD47: role in the immune system and application to cancer therapy. Cell Oncol. 2020;43(1):19–30. doi: 10.1007/s13402-019-00469-5
   Web of Science ®Google Scholar
• Jia X, Yan B, Tian X, et al. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy. Int J Biol Sci. 2021;17(13):3281–3287. doi: 10.7150/ijbs.60782
   PubMed Web of Science ®Google Scholar
• Son J, Hsieh RC, Lin HY, et al. Inhibition of the CD47-SIRPα axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022;13:1027235. doi: 10.3389/fimmu.2022.1027235
   PubMedGoogle Scholar
• Jiang Z, Sun H, Yu J, et al. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14(1):180. doi: 10.1186/s13045-021-01197-w
   PubMed Web of Science ®Google Scholar
• Ishay-Ronen D, Diepenbruck M, Kalathur RKR, et al. Gain fat-lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell. 2019;35(1):17–32.e6. doi: 10.1016/j.ccell.2018.12.002
   PubMed Web of Science ®Google Scholar
• Rousselot P, Prost S, Guilhot J, et al. French CML Group. Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study. Cancer. 2017;123(10):1791–1799. doi: 10.1002/cncr.30490
   PubMed Web of Science ®Google Scholar
• Binzhou Medical College; Zhang Ning. PPAR gamma receptor agonist/anticancer drug co-loaded tannic acid and phospholipid iron nanocomposite and preparation thereof. CN113952458A. 2022.
   Google Scholar
• Laviolette SR, De Felice M, Rusiniak R, et al. Combination of cannabidiol and a PPAR agonist. WO2021203206A1. 2021.
   Google Scholar
• Mankind Pharma Ltd. Pharmaceutical combination of PPAR agonist(s) and sterol absorption inhibitor(s) and use thereof. WO2023026130A1. 2023.
   Google Scholar
• Bordeaux U. Centre Hospitalier Univ Bordeaux, Inst Nat Sante Rech Med. Composition comprising PPAR-modulator and an urolithin derivative and uses thereof. EP4085906A1. 2022.
   Google Scholar
• Ventura-Clapier R, Garnier A, Veksler V, et al. Bioenergetics of the failing heart. Biochim Biophys Acta. 2011;1813(7):1360–72. doi: 10.1016/j.bbamcr.2010.09.006
   PubMed Web of Science ®Google Scholar
• Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875. doi: 10.3390/cells9040875
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362–376. doi: 10.1007/s00535-017-1415-1
   PubMed Web of Science ®Google Scholar
• Kinarus Ag. Combinations of PPAR agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases. EP3820526A1. 2021.
   Google Scholar
• Antakly T PPAR-gamma activators, HDAC inhibitors and their therapeutical usages. US11497723B1. 2022.
   Google Scholar
• Tyra Biosciences Inc. Therapies with PPAR agonists and FGFR4 inhibitors. WO2023225334A1. 2023.
   Google Scholar
• Laboratorios Silanes, S.A. de C.V. Pharmaceutical combinations of statins and fibrates for the treatment and prevention of hyperlipidaemia and cardiovascular diseases. EP4180036A1. 2023.
   Google Scholar
• First Affiliated Hospital of Xiamen Univ, Shenzhen Chipscreen Biosciences Co Ltd, Chengdu Chipscreen Pharmaceutical Ltd. Use of PPAR agonist in preparation of drug for treating acute myeloid leukemia. WO2023072010A1. 2023.
   Google Scholar
• Genfit. PPAR-agonists for use in the treatment of liver failure. WO2022238445A1. 2022.
   Google Scholar
• Zhongshan Hospital Fudan Univ. Application of PPAR-gamma agonist rosiglitazone in sleep apnea related hypertension. CN115944633A. 2023.
   Google Scholar
• Yuan F, Zhang S, Liu X, et al. Correlation between obstructive sleep apnea hypopnea syndrome and hypertension: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(12):12251–12261. doi: 10.21037/apm-21-3302
   PubMed Web of Science ®Google Scholar
• Sullivan SS, Guilleminault C. Emerging drugs for common conditions of sleepiness: obstructive sleep apnea and narcolepsy. Expert Opin Emerg Drugs. 2015;20(4):571–82. doi: 10.1517/14728214.2015.1115480
   PubMed Web of Science ®Google Scholar
• Potenza MA, Gagliardi S, De Benedictis L, et al. Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am J Physiol Endocrinol Metab. 2009;297(3):E685–94. doi: 10.1152/ajpendo.00291.2009
   PubMed Web of Science ®Google Scholar
• Univ Zhongshan. Application of peroxisome proliferator-activated receptor agonist in preparation of anti-aging drugs. CN116999550A. 2023)
   Google Scholar
• Merk D, Lamers C, Weber J, et al. Anthranilic acid derivatives as nuclear receptor modulators–development of novel PPAR selective and dual PPAR/FXR ligands. Bioorg Med Chem. 2015;23(3):499–514. doi: 10.1016/j.bmc.2014.12.013
   PubMed Web of Science ®Google Scholar
• Lillich FF, Willems S, Ni X, et al. Structure-based design of dual partial peroxisome proliferator-activated receptor γ agonists/soluble epoxide hydrolase inhibitors. J Med Chem. 2021;64(23):17259–17276. doi: 10.1021/acs.jmedchem.1c01331
   PubMed Web of Science ®Google Scholar
• Tilekar K, Hess JD, Upadhyay N, et al. Thiazolidinedione “magic bullets” simultaneously targeting PPARγ and HDACs: design, synthesis, and investigations of their in vitro and in vivo antitumor effects. J Med Chem. 2021;64(10):6949–6971. doi: 10.1021/acs.jmedchem.1c00491
   PubMed Web of Science ®Google Scholar
• De Lellis L, Cimini A, Veschi S, et al. The anticancer potential of peroxisome proliferator-activated receptor antagonists. ChemMedchem. 2018;13(3):209–219. doi: 10.1002/cmdc.201700703
   PubMed Web of Science ®Google Scholar
• Stebbins KJ, Broadhead AR, Cabrera G, et al. In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist. Eur J Pharmacol. 2017;809:130–140. doi: 10.1016/j.ejphar.2017.05.008
   PubMed Web of Science ®Google Scholar
• Ammazzalorso A, Bruno I, Florio R, et al. Sulfonimide and amide derivatives as novel PPARα antagonists: synthesis, antiproliferative activity, and docking studies. ACS Med Chem Lett. 2020;11(5):624–632. doi: 10.1021/acsmedchemlett.9b00666
   PubMed Web of Science ®Google Scholar